FDA patience runs out for ProAmatine proof; Tauzin: PhRMA re-orientation ill advised;

> The FDA, wondering where the post-approval studies are that it required in 1996 as part of an accelerated approval, now proposes withdrawing that approval for ProAmatine (midodrine hydrochloride), used to treat a low blood pressure condition. Release

> Billy Tauzin advises new PhRMA leadership not to try turning back the "big ship" that he took "a long time turning." Item

> Mathi Senapathi has joined Radient as manufacturing director, responsible for the Onko-Sure in vitro diagnostic cancer test kits. Release

> Africa's Aspen Pharmacare will buy Australia's Sigma's pharmaceutical division, which manufactures generic and branded drugs. Article (sub. req.)

> EnWave is testing a multiple-vial prototype of its dehydration technology for standard industry serum vials containing vaccines, injectable drugs, analytical enzymes, diagnostic reagents, antibodies and other biological materials. Release

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.